

in which

Sub
E1
X

R¹ is (C₁-C₈)-alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkyl-S(O)_m-, R⁵R⁶N and aryl; (C₃-C₉)-cycloalkyl, which can be substituted by one or more identical or different substituents chosen from (C₁-C₄)-alkyl, hydroxyl and amino; or a radical of a 5-membered to 7-membered saturated heterocyclic ring with one or two identical or different hetero ring members chosen from O, NR⁷ and S(O)_m and that can be substituted by one or more identical or different substituents chosen from (C₁-C₄)-alkyl and aryl-(C₁-C₄)-alkyl-; and

R² is hydrogen, (C₁-C₈)-alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkyl-S(O)_m-, R⁵R⁶N and aryl; (C₃-C₉)-cycloalkyl, which can be substituted by one or more identical or different substituents chosen from (C₁-C₄)-alkyl, hydroxyl and amino; or the radical of a 5-membered to 7-membered saturated heterocyclic ring with one or two identical or different hetero ring members chosen from O, NR⁷ and S(O)_m and that can be substituted by one or more identical or different substituents chosen from (C₁-C₄)-alkyl and aryl-(C₁-C₄)-alkyl-; or

R¹R²N is a radical, bonded via a ring nitrogen atom, of a 5-membered to 7-membered saturated heterocyclic ring optionally with, in addition to the nitrogen atom carrying the radicals R¹ and R², a further hetero ring

member chosen from O, NR^7 and S(O)_m and that can be substituted by one or more identical or different substituents chosen from (C₁-C₄)-alkyl, hydroxyl, (C₁-C₄)-alkoxy, $\text{R}^8\text{R}^9\text{N}$, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl and $\text{R}^8\text{R}^9\text{N-CO-}$;

Sub
E1
DI
 R^3 is phenyl, which can be substituted by one or more identical or different substituents chosen from halogen, (C₁-C₄)-alkyl, phenyl, CF_3 , NO_2 , OH, -O-(C₁-C₄)-alkyl, -O-(C₂-C₄)-alkyl-O-(C₁-C₄)-alkyl, (C₁-C₂)-alkylenedioxy, NH_2 , -NH-(C₁-C₄)-alkyl, $\text{N}((\text{C}_1\text{-C}_4)\text{-alkyl})_2$, -NH-CHO, -NH-CO-(C₁-C₄)-alkyl, -CN, -CO-NH₂, -CO-NH-(C₁-C₄)-alkyl, -CO-N((C₁-C₄)-alkyl)₂, -CO-OH, -CO-O-(C₁-C₄)-alkyl, -CHO and -CO-(C₁-C₄)-alkyl;

R^4 is (C₂-C₅)-alkyl, trifluoromethyl or phenyl, which can be substituted by one or more identical or different substituents chosen from halogen, (C₁-C₄)-alkyl, phenyl, CF_3 , NO_2 , OH, -O-(C₁-C₄)-alkyl, -O-(C₂-C₄)-alkyl-O-(C₁-C₄)-alkyl, (C₁-C₂)-alkylenedioxy, NH_2 , -NH-(C₁-C₄)-alkyl, $\text{N}((\text{C}_1\text{-C}_4)\text{-alkyl})_2$, -NH-CHO, -NH-CO-(C₁-C₄)-alkyl, -CN, -CO-NH₂, -CO-NH-(C₁-C₄)-alkyl, -CO-N((C₁-C₄)-alkyl)₂, -CO-OH, -CO-O-(C₁-C₄)-alkyl, -CHO and -CO-(C₁-C₄)-alkyl;

R^5 and R^6 are identical or different radicals chosen from hydrogen and (C₁-C₄)-alkyl; or the group $\text{R}^5\text{R}^6\text{N}$ is a radical, bonded via a ring nitrogen atom, of a 5-membered to 7-membered saturated or unsaturated heterocyclic ring optionally with, in addition to the nitrogen atom carrying the radicals R^5 and R^6 , a further hetero ring member chosen from an oxygen atom, a group S(O)_m and a nitrogen atom and that can carry on ring carbon atoms one or more identical or different substituents chosen from (C₁-C₄)-alkyl, hydroxyl and amino and that can carry on a ring nitrogen atom a radical R^7 ;

R^7 is hydrogen, (C₁-C₄)-alkyl, aryl-(C₁-C₄)-alkyl-, hydroxy-(C₁-C₄)-alkyl, hydroxycarbonyl-(C₁-C₄)-alkyl-, ((C₁-C₄)-alkoxycarbonyl)-(C₁-C₄)-alkyl, $\text{R}^8\text{R}^9\text{N-CO-(C}_1\text{-C}_4\text{)-alkyl-}$, $\text{R}^{10}\text{-SO}_2\text{-}$ or aryl; where R^7 , if this group is

FINNEGAN
ENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

present on a piperazino radical representing R^1R^2N , cannot be carbocyclic aryl or carbocyclic aryl-(C^1-C^4)-alkyl;

R^8 and R^9 are identical or different radicals chosen from hydrogen and (C_1-C_4)-alkyl;

R^{10} is (C_1-C_4)-alkyl, aryl or R^8R^9N ;

Sub
E1
D1
aryl is phenyl, naphthyl or heteroaryl, all of which can be substituted by one or more identical or different substituents chosen from halogen, (C_1-C_4)-alkyl, phenyl, CF_3 , NO_2 , OH , $-O-(C_1-C_4)$ -alkyl, $O-(C_2-C_4)$ -alkyl- $O-(C_1-C_4)$ -alkyl, (C_1-C_2)-alkylenedioxy, NH_2 , $-NH-(C_1-C_4)$ -alkyl, $-N((C_1-C_4)-alkyl)_2$, $-NH-CHO$, $-NH-CO-(C_1-C_4)$ -alkyl, $-CN$, $CO-NH_2$, $-CO-NH-(C_1-C_4)$ -alkyl, $-CO-N((C_1-C_4)-alkyl)_2$, $-CO-OH$, $-CO-O-(C_1-C_4)$ -alkyl, $-CHO$ and $-CO-(C_1-C_4)$ -alkyl;

heteroaryl is the radical of a monocyclic 5-membered or 6-membered aromatic heterocycle or of a bicyclic 8-membered to 10-membered aromatic heterocycle, each of which with one or more identical or different ring heteroatoms chosen from N, O and S;

m is 0, 1 or 2;

or a stereoisomeric form of a compound of formula I,

or a mixture of stereoisomeric forms of compounds of formula I in all ratios,

or a physiologically tolerable salt of a compound of formula I,

or a physiologically tolerable salt of a stereoisomeric form of a compound of formula I;

compounds of the formula I being excluded in which, simultaneously, R^4 is ethyl, tert-butyl, or trifluoromethyl; R^3 is phenyl, which can be substituted by one or two

Sub
E1
identical or different substituents chosen from halogen, OH, -O-R¹¹ and CF₃,
R¹R²N is R¹¹ -NH-, (R¹¹)₂N- or R¹²R¹³N-(CH₂)_p-NH-; p is 2 or 3; R¹¹ is saturated
unsubstituted (C₁-C₄)-alkyl; and R¹² and R¹³ are identical or different radicals
chosen from hydrogen and R¹¹ or the group R¹²R¹³N is a radical, bonded via a
ring nitrogen atom, of a 5-membered or 6-membered saturated heterocyclic ring
optionally with, in addition to the nitrogen atom carrying the radicals R¹² and R¹³,
a further hetero ring member chosen from an oxygen atom, a sulfur atom and a
nitrogen atom and that can be substituted by an aryl substituted by one or two
identical or different substituents chosen from halogen, OH, -O-R¹¹, and CF₃.

2. A compound of claim 1, in which

Sub
E1
R¹ is (C₁-C₈)-alkyl, which can be substituted by one or more identical or different
substituents, chosen from, hydroxyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkyl-S(O)_m-,
R⁵R⁶N and aryl; or is (C₃-C₉)-cycloalkyl, which can be substituted by one
or more identical or different substituents chosen from (C₁-C₄)-alkyl,
hydroxyl and amino; and

R² is hydrogen, (C₁-C₈)-alkyl, which can be substituted by one or more identical
or different substituents chosen from hydroxyl, (C₁-C₄)-alkoxy, (C₁-C₄)-
alkyl-S(O)_m-, R⁵R⁶N and aryl; or is (C₃-C₉)-cycloalkyl, which can be
substituted by one or more identical or different substituents chosen from
(C₁-C₄)-alkyl, hydroxyl and amino; or




R¹R²N is a radical, bonded via a ring nitrogen atom of a 5-membered, 6-
membered or 7-membered saturated heterocyclic ring optionally with, in
addition to the nitrogen atom carrying the radicals R¹ and R², a further
hetero ring member chosen from an oxygen atom, a group S(O)_m and a
nitrogen atom carrying a radical R⁷ and that can be substituted by one or
more identical or different substituents chosen from (C₁-C₄)-alkyl,
hydroxyl, (C₁-C₄)-alkoxy, R⁸R⁹N, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl
and R⁸R⁹N-CO.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

8. A process for the preparation of at least one compound of claim 1, which comprises activating a 4-hydroxypyrimidine of the formula IV and then reacting it with an amine of a formula VI to produce a compound of formula I,

Sub
EI
D3



and optionally converting a compound of formula I into a pharmaceutically acceptable salt.

15. A process for the preparation of at least one compound of claim 5, which comprises activating a 4-hydroxypyrimidine of the formula IV and then reacting it with an amine of a formula VI;


D4

Sub
EI

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com


24
Sub
E1



and optionally converting the resulting product into a pharmaceutically acceptable salt.

22. A method of treating a cardiovascular disorder associated with low cGMP levels, or a disorder for whose therapy or prophylaxis an increase in the cGMP levels is desired, comprising administering to a patient in need thereof an effective amount of at least one compound of formula I,

DS



in which

R^1 is (C₁-C₈)-alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkyl-S(O)_m, R^5R^6N and aryl; (C₃-C₉)-cycloalkyl, which can be substituted by one or

more identical or different substituents chosen from (C₁-C₄)-alkyl, hydroxyl and amino; or a radical of a 5-membered to 7-membered saturated heterocyclic ring with one or two identical or different hetero ring members chosen from O, NR⁷ and S(O)_m and that can be substituted by one or more identical or different substituents chosen from (C₁-C₄)-alkyl and aryl-(C₁-C₄)-alkyl-; and

DS
R² is hydrogen, (C₁-C₈)-alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkyl-S(O)_m-, R⁵R⁶N and aryl; (C₃-C₉)-cycloalkyl, which can be substituted by one or more identical or different substituents chosen from (C₁-C₄)-alkyl, hydroxyl and amino; or the radical of a 5-membered to 7-membered saturated heterocyclic ring with one or two identical or different hetero ring members chosen from O, NR⁷ and S(O)_m and that can be substituted by one or more identical or different substituents chosen from (C₁-C₄)-alkyl and aryl-(C₁-C₄)-alkyl-; or

R¹R²N is a radical, bonded via a ring nitrogen atom, of a 5-membered to 7-membered saturated heterocyclic ring optionally with, in addition to the nitrogen atom carrying the radicals R¹ and R², a further hetero ring member chosen from O, NR⁷ and S(O)_m and that can be substituted by one or more identical or different substituents chosen from (C₁-C₄)-alkyl, hydroxyl, (C₁-C₄)-alkoxy, R⁸R⁹N, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl and R⁸R⁹N-CO-;

R³ is phenyl, which can be substituted by one or more identical or different substituents chosen from halogen, (C₁-C₄)-alkyl, phenyl, CF₃, NO₂, OH, -O-(C₁-C₄)-alkyl, -O-(C₂-C₄)-alkyl-O-(C₁-C₄)-alkyl, (C₁-C₂)-alkylenedioxy, NH₂, -NH-(C₁-C₄)-alkyl, N((C₁-C₄)-alkyl)₂, -NH-CHO, -NH-CO-(C₁-C₄)-alkyl, -CN, -CO-NH₂, -CO-NH-(C₁-C₄)-alkyl, -CO-N((C₁-C₄)-alkyl)₂, -CO-OH, -CO-O-(C₁-C₄)-alkyl, -CHO and -CO-(C₁-C₄)-alkyl;

R^4 is (C₂-C₅)-alkyl, trifluoromethyl or phenyl, which can be substituted by one or more identical or different substituents chosen from halogen, (C₁-C₄)-alkyl, phenyl, CF₃, NO₂, OH, -O-(C₁-C₄)-alkyl, -O-(C₂-C₄)-alkyl-O-(C₁-C₄)-alkyl, (C₁-C₂)-alkylenedioxy, NH₂, -NH-(C₁-C₄)-alkyl, N((C₁-C₄)-alkyl)₂, -NH-CHO, -NH-CO-(C₁-C₄)-alkyl, -CN, -CO-NH₂, -CO-NH-(C₁-C₄)-alkyl, -CO-N((C₁-C₄)-alkyl)₂, -CO-OH, -CO-O-(C₁-C₄)-alkyl, -CHO and -CO-(C₁-C₄)-alkyl;

05 R^5 and R^6 are identical or different radicals chosen from hydrogen and (C₁-C₄)-alkyl; or the group R^5R^6N is a radical, bonded via a ring nitrogen atom, of a 5-membered to 7-membered saturated or unsaturated heterocyclic ring optionally with, in addition to the nitrogen atom carrying the radicals R^5 and R^6 , a further hetero ring member chosen from an oxygen atom, a group S(O)_m and a nitrogen atom and that can carry on ring carbon atoms one or more identical or different substituents chosen from (C₁-C₄)-alkyl, hydroxyl and amino and that can carry on a ring nitrogen atom a radical R^7 ;

R^7 is hydrogen, (C₁-C₄)-alkyl, aryl-(C₁-C₄)-alkyl-, hydroxy-(C₁-C₄)-alkyl, hydroxycarbonyl-(C₁-C₄)-alkyl-, ((C₁-C₄)-alkoxycarbonyl)-(C₁-C₄)-alkyl, R^8R^9N -CO-(C₁-C₄)-alkyl-, R^{10} -SO₂- or aryl; where R^7 , if this group is present on a piperazino radical representing R^1R^2N , cannot be carbocyclic aryl or carbocyclic aryl-(C¹-C⁴)-alkyl;

R^8 and R^9 are identical or different radicals chosen from hydrogen and (C₁-C₄)-alkyl;

R^{10} is (C₁-C₄)-alkyl, aryl or R^8R^9N ;

aryl is phenyl, naphthyl or heteroaryl, all of which can be substituted by one or more identical or different substituents chosen from halogen, (C₁-C₄)-alkyl, phenyl, CF₃, NO₂, OH, -O-(C₁-C₄)-alkyl, O-(C₂-C₄)-alkyl-O-(C₁-C₄)-alkyl, (C₁-C₂)-alkylenedioxy, NH₂, -NH-(C₁-C₄)-alkyl, -N((C₁-C₄)-alkyl)₂, -NH-

CHO, -NH-CO-(C₁-C₄)-alkyl, -CN, CO-NH₂, -CO-NH-(C₁-C₄)-alkyl, -CO-N((C₁-C₄)-alkyl)₂, -CO-OH, -CO-O-(C₁-C₄)-alkyl, -CHO and -CO-(C₁-C₄)-alkyl;

heteroaryl is the radical of a monocyclic 5-membered or 6-membered aromatic heterocycle or of a bicyclic 8-membered to 10-membered aromatic heterocycle, each of which with one or more identical or different ring heteroatoms chosen from N, O and S;

m is 0, 1 or 2;

or a stereoisomeric form of a compound of formula I,

or a mixture of stereoisomeric forms of compounds of formula I in all ratios,

or a physiologically tolerable salt of a compound of formula I,

or a physiologically tolerable salt of a stereoisomeric form of a compound of formula I.

REMARKS

I. Status of the claims

After entering this amendment, claims 1-8, 11-15, and 18-23 are pending in this application. Claims 10 and 17 have been cancelled with the sole purpose of expediting prosecution. Applicants reserve the right to pursue protection for the subject matter of claims 10 and 17 in a continuation application or at a later stage of prosecution. Claims 1, 2, 8, and 15 have been amended to more clearly define the invention. Support for these amendments can be found in originally-filed claims 1, 2, 8, and 15. Claim 22 has been amended to more clearly define the invention. Support for this amendment can be